Article
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2010
Heon Stephanie, Yeap Beow Y, Britt Gregory J, Costa Daniel B, Rabin Michael S, Jackman David M, Johnson Bruce E
Abstract excerpt
PURPOSE: Gefitinib and erlotinib can penetrate into the central nervous system (CNS) and elicit responses in patients with brain metastases (BM) from non-small cell lung cancer (NSCLC). However, there are incomplete data about their impact on the development and control of CNS metastases. EXPERIMENTAL DESIGN: Patients with stage IIIB/IV NSCLC with somatic EGFR mutations initially treated with gefitinib or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
